The use of acetazolamide for the prevention of high-altitude illness.
Acetazolamide
acute mountain sickness
high-altitude illness
incidence of altitude illness
Journal
Journal of travel medicine
ISSN: 1708-8305
Titre abrégé: J Travel Med
Pays: England
ID NLM: 9434456
Informations de publication
Date de publication:
26 Sep 2020
26 Sep 2020
Historique:
received:
27
09
2019
revised:
05
12
2019
accepted:
19
12
2019
pubmed:
4
1
2020
medline:
29
7
2021
entrez:
4
1
2020
Statut:
ppublish
Résumé
Modern travel means that many travellers can arrive abruptly to high-altitude destinations without doing any trekking or climbing. Airports in high-altitude cities mean that travellers can go from sea level to over 3350-3960 m (11 000-13 000 feet) in a matter of hours, putting themselves at risk for high-altitude illness (HAI). Acetazolamide has been shown to be an effective way to help prevent HAI on such itineraries. The risk of HAI on rapid arrival to altitudes over 3350 m (11 000 feet) has been shown to range from 35% to nearly 50%. The risk can be higher for high-altitude trekking. This risk is far higher than most travel medicine risks and is on a par with the risk of travellers' diarrhea in high risk destinations. The use of prophylactic acetazolamide in a dosage of 125 mg every 12 h is highly effective at diminishing the risk of HAI. Travel medicine practitioners should become comfortable with assessing the risk of HAI and determining when it is appropriate to offer acetazolamide prophylaxis to prevent HAI.
Sections du résumé
BACKGROUND
BACKGROUND
Modern travel means that many travellers can arrive abruptly to high-altitude destinations without doing any trekking or climbing. Airports in high-altitude cities mean that travellers can go from sea level to over 3350-3960 m (11 000-13 000 feet) in a matter of hours, putting themselves at risk for high-altitude illness (HAI).
METHODS
METHODS
Acetazolamide has been shown to be an effective way to help prevent HAI on such itineraries. The risk of HAI on rapid arrival to altitudes over 3350 m (11 000 feet) has been shown to range from 35% to nearly 50%. The risk can be higher for high-altitude trekking. This risk is far higher than most travel medicine risks and is on a par with the risk of travellers' diarrhea in high risk destinations.
RESULT
RESULTS
The use of prophylactic acetazolamide in a dosage of 125 mg every 12 h is highly effective at diminishing the risk of HAI.
CONCLUSION
CONCLUSIONS
Travel medicine practitioners should become comfortable with assessing the risk of HAI and determining when it is appropriate to offer acetazolamide prophylaxis to prevent HAI.
Identifiants
pubmed: 31897486
pii: 5693888
doi: 10.1093/jtm/taz106
pii:
doi:
Substances chimiques
Acetazolamide
O3FX965V0I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© International Society of Travel Medicine 2020. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.